Hepatitis B flare: the good, the bad and the ugly
暂无分享,去创建一个
[1] Y. Liaw,et al. Evidence-Based Management of Oral Nucleos(t)ide Analogue Withdrawal in Virally Suppressed Patients with Chronic HBV Infection , 2022, Current Hepatology Reports.
[2] Y. Liaw,et al. The role of off-therapy viral kinetics in the timing and severity of flares in hepatitis B e antigen-negative patients. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] Y. Liaw,et al. Robust antiviral responses in severe hepatitis flare persist after early retreatment cessation and lead toward hepatitis B surface antigen loss: A proof‐of‐concept study , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.
[4] Y. Liaw,et al. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen‐negative chronic hepatitis B: From an “option” to an “active recommendation” , 2022, The Kaohsiung journal of medical sciences.
[5] Y. Liaw,et al. Current Trend in Antiviral Therapy for Chronic Hepatitis B , 2022, Viruses.
[6] Y. Liaw,et al. Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses , 2022, International journal of molecular sciences.
[7] Y. Liaw,et al. Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[8] Y. Liaw,et al. Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment. , 2021, The Journal of antimicrobial chemotherapy.
[9] V. Sundararajan,et al. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis , 2021, Gut.
[10] V. Wong,et al. Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. , 2021, The Journal of infectious diseases.
[11] T. Berg,et al. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analog therapy. , 2021, Journal of hepatology.
[12] Y. Liaw. Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg‐Negative Chronic Hepatitis B: To Retreat or Not to Retreat , 2020, Hepatology.
[13] R. Chung,et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. , 2020, Journal of hepatology.
[14] A. Lok,et al. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. , 2020, The lancet. Gastroenterology & hepatology.
[15] Y. Liaw,et al. Re‐treatment for severe hepatitis flare in HBeAg‐negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics , 2019, Journal of viral hepatitis.
[16] William M. Lee,et al. Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] Y. Liaw. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift , 2019, Hepatology International.
[18] Y. Liaw. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection , 2019, Nature Reviews Gastroenterology & Hepatology.
[19] Guohong Deng,et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. , 2019, Journal of hepatology.
[20] Y. Liaw,et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B , 2018, Hepatology.
[21] Y. Liaw,et al. HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients. , 2018, Gastroenterology.
[22] Y. Liaw,et al. Great and rapid HBsAg decline in patients with on‐treatment hepatitis flare in early phase of potent antiviral therapy , 2018, Journal of viral hepatitis.
[23] Y. Liaw,et al. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. , 2014, Journal of hepatology.
[24] S. Locarnini,et al. Anti‐viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post‐partum flare , 2014, Alimentary pharmacology & therapeutics.
[25] A. Lok,et al. Management of patients with hepatitis B who require immunosuppressive therapy , 2014, Nature Reviews Gastroenterology &Hepatology.
[26] D. Vassilopoulos,et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. , 2012, Gastroenterology.
[27] Jia-Horng Kao,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.
[28] Y. Liaw,et al. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[29] M. Brunetto. A new role for an old marker, HBsAg. , 2010, Journal of hepatology.
[30] J. Stockman,et al. Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B , 2010 .
[31] S. Lewin,et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. , 2009, The Journal of infectious diseases.
[32] R. D. de Man,et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy , 2005, Gut.
[33] Y. Liaw,et al. No Benefit to Continue Lamivudine Therapy after Emergence of Ymdd Mutations , 2004, Antiviral therapy.
[34] A. Bertoletti,et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. , 2003, Journal of hepatology.
[35] Y. Liaw,et al. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B , 2003 .
[36] Y. Liaw,et al. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. , 2003, Journal of hepatology.
[37] M. Brunetto,et al. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. , 2003, Journal of hepatology.
[38] C. Wai,et al. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B , 2002, Gut.
[39] R. Perrillo. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. , 2001, Gastroenterology.
[40] A. Lok,et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .
[41] Y. Liaw,et al. Acute exacerbation in patients with liver cirrhosis: a clinicopathological study. , 2008, Liver.
[42] C. Chan,et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. , 1990, Gastroenterology.
[43] A. Lok,et al. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. , 1990, Journal of hepatology.
[44] C. Chu,et al. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody‐positive patients , 1987, Hepatology.
[45] C. Chu,et al. Changes of serum hepatitis B virus DNA in two types of clinical events preceding spontaneous hepatitis B e antigen seroconversion in chronic type B hepatitis , 1987, Hepatology.
[46] C. Chu,et al. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. , 2008, Liver.
[47] C. Chu,et al. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. , 1985, Gastroenterology.
[48] C. Chu,et al. Acute exacerbation in hepatitis B e antigen positive chronic type B hepatitis. A clinicopathological study. , 1985, Journal of hepatology.
[49] C. Chu,et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. , 1983, Gastroenterology.
[50] H. Popper,et al. The vocabulary of chronic hepatitis. , 1971, The New England journal of medicine.